Finance

Beta

Lists

Equity sectors
Symbols
Symbols
Trend
Change
Price
Change
% Change
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-0.45%
—
1,097.08
-0.45%
1,097.08
-5.00
-0.45%
1,102.081,104.411,110.611,096.10——
SIXC
Communications
SIXC
Communications
SIXC
+0.27%
—
571.79
+0.27%
571.79
+1.56
+0.27%
570.23570.23576.23566.53——
SIXE
Energy
SIXE
Energy
SIXE
-1.69%
—
1,124.31
-1.69%
1,124.31
-19.27
-1.69%
1,143.581,137.641,137.641,113.91——
SIXI
Industrials
SIXI
Industrials
SIXI
+0.72%
—
1,820.63
+0.72%
1,820.63
+12.95
+0.72%
1,807.681,814.861,840.041,814.86——
SIXM
Financials
SIXM
Financials
SIXM
-0.91%
—
658.84
-0.91%
658.84
-6.03
-0.91%
664.87667.28670.86657.59——
SIXR
Staples
SIXR
Staples
SIXR
-0.49%
—
837.82
-0.49%
837.82
-4.10
-0.49%
841.92841.46843.77836.31——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.29%
—
214.08
-0.29%
214.08
-0.63
-0.29%
214.71214.71216.26213.98——
SIXT
Technology
SIXT
Technology
SIXT
+3.08%
—
3,853.63
+3.08%
3,853.63
+115.02
+3.08%
3,738.613,823.543,863.533,812.59——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.66%
—
901.60
+0.66%
901.60
+5.88
+0.66%
895.72896.48913.11896.48——
SIXV
Health care
SIXV
Health care
SIXV
-0.85%
—
1,505.60
-0.85%
1,505.60
-12.95
-0.85%
1,518.551,520.111,520.981,499.19——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+1.51%
—
2,365.50
+1.51%
2,365.50
+35.08
+1.51%
2,330.422,343.432,374.422,332.21——
IMVT:NASDAQ
Immunovant Inc
$35.34
+1.82%
(+0.63) Today
Closed: Jun 18, 4:00:01 PM GMT-4  ·   USD
$35.34
0.00% (0.00)
After hours  ·  4:15 PM
SymbolPriceChange% ChangePrev Close
Generating top insights for IMVT...
Open
$35.15
High
$35.79
Low
$34.40
Mkt. cap
7.26B
Avg. vol.
2.18M
Volume
3.89M
52-wk high
$36.28
52-wk low
$14.32
EPS
-$2.77
Beta
0.76
Shares outstanding
205.31M
No. of employees
315
Open
$35.15
High
$35.79
Low
$34.40
Mkt. cap
7.26B
Avg. vol.
2.18M
Volume
3.89M
52-wk high
$36.28
52-wk low
$14.32
EPS
-$2.77
Beta
0.76
Shares outstanding
205.31M
No. of employees
315
Analyst outlook
Analyst Ratings
Based on 12 analysts giving stock ratings to IMVT in the past 3 months
Strong Buy
Buy
10
Hold
2
Sell
0
12 month forecast
Based on 12 Wall Street analysts offering 12 month price targets for IMVT in the last 3 months.
Highest
Current $35.34
$66.00 (+86.76%)
Average
$46.33 (+31.10%)
Lowest
$30.00 (-15.11%)
News stories
From sources across the web
About Immunovant Inc
CEO-
Employees315
Founded2018
Headquarters-
SectorBiotechnology
Websiteimmunovant.com
Last report
May 20, 2026
Fiscal period
Q4 2026
EPS / Est. (USD)
-$0.73 / -$0.62
-18.09%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q4 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
101.20M
114.25M
98.92M
142.29M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
26.02M
17.51M
15.44M
17.27M
Operating expense
127.22M
131.76M
114.36M
159.55M
Total operating expenses
127.22M
131.76M
114.36M
159.55M
Operating income
-127.22M
-131.76M
-114.36M
-159.55M
Other non operating income
1.19M
250.00K
-54.00K
798.00K
EBT including unusual items
-119.70M
-125.91M
-109.08M
-150.70M
EBT excluding unusual items
-119.70M
-125.91M
-109.08M
-150.70M
Income tax expense
913.00K
594.00K
1.55M
-2.84M
Effective tax rate
-0.76%
-0.47%
-1.42%
1.89%
Other operating expenses
-
-
-
-
Net income
-120.61M
-126.50M
-110.64M
-147.86M
Net profit margin
-
-
-
-
Earnings per share
-0.71
-0.65
-0.54
-0.67
Interest and investment income
6.34M
5.60M
5.33M
8.06M
Interest expense
-
-
-
-
Net interest expenses
6.34M
5.60M
5.33M
8.06M
Depreciation and amortization charges
-
-
-
-
EBITDA
-127.12M
-131.66M
-114.26M
-159.46M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer